Form 8-K - Current report:
SEC Accession No. 0001104659-24-095276
Filing Date
2024-08-30
Accepted
2024-08-30 09:08:49
Documents
14
Period of Report
2024-08-29
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2423119d1_8k.htm   iXBRL 8-K 27356
  Complete submission text file 0001104659-24-095276.txt   246160

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA cycc-20240829.xsd EX-101.SCH 3260
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE cycc-20240829_def.xml EX-101.DEF 26928
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cycc-20240829_lab.xml EX-101.LAB 36551
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cycc-20240829_pre.xml EX-101.PRE 25552
16 EXTRACTED XBRL INSTANCE DOCUMENT tm2423119d1_8k_htm.xml XML 5433
Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-50626 | Film No.: 241266675
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)